TRCT
MEDS

Tower Research Capital (TRC)’s DataMeds AI, Inc. Common Stock MEDS Stock Holding History

Tower Research Capital (TRC)’s Portfolio MEDS Stock Details MEDS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-288
Closed -$5.75K – 5698
2025
Q4 		$5.75K Sell
288
-42
-13% -$1.23K ﹤0.01% 4098
2025
Q3 		$14.7K Buy
+330
New +$17.4K ﹤0.01% 3583

Other funds holding MEDS

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
AA
ACT Advisors Asheville, North Carolina $301M AUM 23.36% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Tower Research Capital (TRC)'s MEDS Position: Q1 2026 in Review

Tower Research Capital (TRC) sold out of DataMeds AI, Inc. Common Stock (MEDS) in Q1 2026, closing a stake of 288 shares — an estimated $5.75K sold.

Tower Research Capital (TRC) first reported a position in MEDS in Q3 2025 and held it in 2 quarters. The position peaked at $14.7K in Q3 2025. 13 funds tracked by Wall St. Rank hold MEDS as of Q1 2026.

  • Tower Research Capital (TRC) reported no remaining DataMeds AI, Inc. Common Stock position as of Q1 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 288 DataMeds AI, Inc. Common Stock shares in Q1 2026, an estimated $5.75K.
  • Tower Research Capital (TRC) first reported a position in DataMeds AI, Inc. Common Stock in Q3 2025 and held it in 2 quarters.
  • Tower Research Capital (TRC)'s DataMeds AI, Inc. Common Stock position peaked at $14.7K in Q3 2025.
  • 13 funds tracked by Wall St. Rank held DataMeds AI, Inc. Common Stock as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.